Introduction
Brain-derived neurotrophic factor (BDNF) is an important member of the classic neurotrophin family of growth factors, along with nerve growth factor, and neurotrophins 3, 4/5 and 6. It regulates neuronal survival, differentiation and plasticity by activating the receptor tyrosine kinase TrkB and p75 low-affinity neurotrophin receptor (Huang and Reichardt, 2001; Poo, 2001) . Reduced BDNF signaling through TrkB leads to impaired spatial memory (Minichiello et al., 1999; Saarelainen et al., 2000; Minichiello, 2009) , while overexpression of TrkB enhances memory (Koponen et al., 2004) . Further, when signaling through TrkB BDNF enhances long-term potentiation (LTP) of hippocampal synapses (Minichiello, 2009) while through p75 it promotes long-term depression (LTD) (Rosch et al., 2005) . These properties of BDNF have led to speculations about its role in Alzheimer's disease (AD) where synaptic and neuronal loss and impaired memory constitute an essential part of the pathology.
Altered BDNF signaling in AD brains
BDNF mRNA and protein levels have been found to be reduced in postmortem brain samples of AD patients (Phillips et al., 1991; Narisawa-Saito et al., 1996; Connor et al., 1997; Ferrer et al., 1999; Holsinger et al., 2000; Hock et al., 2000; Garzon et al., 2002; Fahnestock et al., 2002) . Importantly, reduced BDNF levels were reported already at the mild cognitive impairment (MCI) stage of the disease in one study and were shown to correlate with cognitive function (Peng et al., 2005) . This is consistent with findings in our brain bank
